Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 7:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 588 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Aspirin Clear all
Completed Not applicable Interventional Results available

Nudge to Drive Transitions of Care

NCT04660032
View directory record Official record
Conditions
Preeclampsia, Preeclampsia Severe, Gestational Hypertension, Hypertensive Disorder of Pregnancy, Superimposed Pre-Eclampsia
Interventions
Nudge
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Female only
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Oct 19, 2026, 7:56 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)

NCT02164864
View directory record Official record
Conditions
Atrial Fibrillation, Percutaneous Coronary Intervention
Interventions
Dabigatran Etexilate 110mg, Warfarin 3mg, Aspirin, Dabigatran Etexilate 150mg, Clopidogrel or Ticagrelor, Warfarin 5mg, Warfarin 1mg
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
2,725 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
45
States / cities
Birmingham, Alabama • Cottonwood, Arizona • Mesa, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 19, 2026, 7:56 PM EDT
Completed Not applicable Interventional

High Omega-3/Low Omega-6 Treatment Diet for Aspirin-exacerbated Respiratory Disease (AERD)

NCT02064738
View directory record Official record
Conditions
ASA Triad, Asthma, Nasal Polyps, And Aspirin Intolerance
Interventions
Restricting daily intake of omega-6 fatty acids to less than 4 grams and increasing omega-3 fatty acids to 3 grams
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Oct 19, 2026, 7:56 PM EDT
Completed No phase listed Observational

Antenatal Platelet Response On Aspirin and Correlation With HDP (Hypertensive Disorders of Pregnancy)

NCT04295850
View directory record Official record
Conditions
Preeclampsia
Interventions
Aspirin 81 mg
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
10 Years to 60 Years · Female only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 19, 2026, 7:56 PM EDT
Suspended Not applicable Interventional

Operative Procedures Vs. Endovascular Neurosurgery for Untreated Pseudotumor Trial

NCT02513914
View directory record Official record
Conditions
Pseudotumor Cerebri, Idiopathic Intracranial Hypertension (IIH)
Interventions
Dural Venous Sinus Stenting, Cerebrospinal Fluid Shunting
Device
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Phoenix, Arizona • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Oct 19, 2026, 7:56 PM EDT
Completed Phase 1 Interventional

Nitric Oxide-Releasing Acetylsalicyclic Acid in Preventing Colorectal Cancer in Patients at High Risk of Colorectal Cancer

NCT00331786
View directory record Official record
Conditions
Colorectal Cancer
Interventions
nitric oxide-releasing acetylsalicylic acid derivative, laboratory biomarker analysis, biopsy
Drug · Other · Procedure
Lead sponsor
Stony Brook University
Other
Eligibility
50 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Feb 9, 2009 · Synced Oct 19, 2026, 7:56 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Effect of Postoperative Ketorolac on Bone Healing After Joint Fusion

NCT04872283
View directory record Official record
Conditions
Ketorolac, Joint Fusion
Interventions
great toe (1st metatarsophalangeal joint) fusion, IV Ketorolac, Ketorolac Pill, 5/325mg Oxycodone-Acetaminophen, Aspirin 81Mg Ec Tab
Procedure · Drug
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Oct 19, 2026, 7:56 PM EDT
Completed Not applicable Interventional

Translating the ABCS Into HIV Care

NCT03902431
View directory record Official record
Conditions
HIV, Cardiovascular Risk Factor
Interventions
ABCS training
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
40 Years to 79 Years
Enrollment
4,277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 19, 2026, 7:56 PM EDT
Completed No phase listed Observational

A Comparison of microRNA Samples in Patients With Nasal Polyps and Aspirin Exacerbated Respiratory Disease and Those With Nasal Polyps Only

NCT01631773
View directory record Official record
Conditions
Aspirin-exacerbated Respiratory Disease, Nasal Polyp
Interventions
microRNA
Genetic
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 7, 2014 · Synced Oct 19, 2026, 7:56 PM EDT
Enrolling by invitation Phase 4 Interventional Accepts healthy volunteers

PFA 100 Evaluation and Reference Interval HOACNY

NCT06100510
View directory record Official record
Conditions
Effect of Drug
Interventions
Aspirin 325mg
Drug
Lead sponsor
Hematology Oncology Associates of Central New York
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
East Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Oct 19, 2026, 7:56 PM EDT
Recruiting Phase 2 Interventional

A Polypill for Acute Coronary Syndrome

NCT07032389
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Polypill
Combination Product
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
4
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 19, 2026, 7:56 PM EDT
Completed Phase 1 Interventional

Electrophilic Fatty Acid Derivatives in Asthma

NCT01733485
View directory record Official record
Conditions
Asthma, Electrophilic Fatty Acids
Interventions
Aspirin, Indomethacin
Drug
Lead sponsor
Sally E. Wenzel MD
Other
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 19, 2026, 7:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AZD3366 in Healthy Subjects, Japanese and Chinese Subjects

NCT04588727
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
AZD3366, Placebo, Ticagrelor, acetylsalicylic acid (ASA)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Oct 19, 2026, 7:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Compare the Gastroprotective Effects and Pharmacokinetic Profile of PA Versus Enteric-Coated Aspirin

NCT00442052
View directory record Official record
Conditions
Healthy
Interventions
aspirin, omeprazole
Drug
Lead sponsor
POZEN
Industry
Eligibility
50 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 1, 2007 · Synced Oct 19, 2026, 7:56 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effects of Recombinant Human Erythropoietin on Platelet Function in Healthy Subjects

NCT00368238
View directory record Official record
Conditions
Healthy Subjects
Interventions
Recombinant human erythropoietin alfa (drug), Aspirin (drug), Clopidogrel (drug)
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 40 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 24, 2006 · Synced Oct 19, 2026, 7:56 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects

NCT01646814
View directory record Official record
Conditions
Gastroduodenal Ulceration
Interventions
PL2200, Aspirin tablets
Drug
Lead sponsor
PLx Pharma
Industry
Eligibility
50 Years to 75 Years
Enrollment
247 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
10
States / cities
Jupiter, Florida • South Miami, Florida • Towson, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2022 · Synced Oct 19, 2026, 7:56 PM EDT
Terminated Phase 4 Interventional Results available

Aspirin and Enoxaparin for VTE in Trauma

NCT02396732
View directory record Official record
Conditions
Venous Thromboembolism, Thromboprophylaxis, Trauma
Interventions
Aspirin, Enoxaparin
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 19, 2026, 7:56 PM EDT
Completed Phase 4 Interventional Results available

Pharmacogenomics of Antiplatelet Response - II (PARes-II)

NCT01894555
View directory record Official record
Conditions
Atherothrombosis
Interventions
Aspirin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
45 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 19, 2026, 7:56 PM EDT
Completed Phase 4 Interventional

Clopidogrel and Aspirin Together: The Effect on C-Reactive Protein Trial

NCT00343876
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
aspirin, clopidogrel
Drug
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 21, 2008 · Synced Oct 19, 2026, 7:56 PM EDT
Active, not recruiting Not applicable Interventional

LEADERS FREE II: BioFreedom™ Pivotal Study

NCT02843633
View directory record Official record
Conditions
Acute Coronary Syndrome, High Bleeding Risk
Interventions
BioFreedom™ Drug Coated Coronary Stent System, Antiplatelet Drug
Device · Drug
Lead sponsor
Biosensors Europe SA
Industry
Eligibility
Not listed
Enrollment
1,203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
39
States / cities
Huntsville, Alabama • Hot Springs, Arkansas • La Jolla, California + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 19, 2026, 7:56 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy

NCT07762703
View directory record Official record
Conditions
Triple-Negative Breast Cancer (TNBC)
Interventions
BreakVax, Ipilimumab 2.5 mg, Pembrolizumab, Standard-of-care chemotherapy, Losartan and aspirin
Drug
Lead sponsor
BreakBio Corp
Industry
Eligibility
18 Years to 72 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 19, 2026, 7:56 PM EDT
Recruiting Early Phase 1 Interventional

Daily Aspirin Treatment After Preeclampsia

NCT06168461
View directory record Official record
Conditions
Preeclampsia
Interventions
Aspirin, Placebo
Drug
Lead sponsor
Anna Stanhewicz, PhD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 19, 2026, 7:56 PM EDT
Completed No phase listed Observational

Patients Undergoing Percutaneous Coronary Intervention (PCI) Through Optimal Platelet Inhibition

NCT01582217
View directory record Official record
Conditions
Percutaneous Coronary Intervention, Dual Antiplatelet Therapy, Aspirin, Clopidogrel
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 23, 2015 · Synced Oct 19, 2026, 7:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Administration of an Oral Anti-thrombotic With Antiplatelet Therapy in Healthy Subjects

NCT03698513
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-986177, Placebo (for BMS-986177), Clopidogrel, Aspirin
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
113 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Oct 19, 2026, 7:56 PM EDT